晚期卵巢癌化疗中CA125下降的临床意义 Clinical significance of CA125 regression in chemotherapy of advanced ovarian cancer.pdfVIP

下载本文档

16
0
约 4页
2015-09-01 发布于湖北
举报
版权申诉

晚期卵巢癌化疗中CA125下降的临床意义 Clinical significance of CA125 regression in chemotherapy of advanced ovarian cancer.pdf

1、有哪些信誉好的足球投注网站（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
4、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
5、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
6、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
7、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

晚期卵巢癌化疗中CA125下降的临床意义 Clinical significance of CA125 regression in chemotherapy of advanced ovarian cancer.pdf

Chinese-German Journal of Clinical Oncology March 2012, Vol. 11, No. 3, P160–P163 DOI 10.1007/s10330-011-0932-2 Clinical significance of CA125 regression in chemotherapy of advanced ovarian cancer Yuanjing Hu, Pengpeng Qu Department of Gynecologic Oncology, Tianjin Central Hospital of Gynecology Obstetrics, Tianjin 300100, China Received: 16 November 2011 / Revised: 20 January 2012 / Accepted: 15 February 2012 © Huazhong University of Science and Technology and Springer-Verlag Berlin Heidelberg 2012 Abstract Objective: The aim of this study was to compare the serum CA125 regression in advanced ovarian carcinoma patients treated with paclitaxel/platinum (TP) and platinum/epirubicin/ifosfamide (PAC) during early chemotherapy. The rela- tionship between survival and CA125 regression during first line chemotherapy was evaluated. Methods: This retrospective investigation assessed 122 and 95 patients with stages IIc–IV ovarian carcinoma who underwent initial surgery followed by TP or PAC chemotherapy, respectively. Only epithelial ovarian cancers were included. CA125 half-life was calculated by mono-compartmental logarithmic regression. Every patient’s nadir CA125 concentration was also studied. T-test was used in comparing CA125 half-life and nadir CA125 between two groups. Survival analyses for progression-free survival (PFS) and overall survival (OS) used univariate (Kaplan-Meier) and multivariate (Cox) models for all of the patients. Results: There was not significant difference in CA125 half-life and nadir CA125 concentration between two groups (P 0.05). CA125 half-life and nadir CA125 concentration had a univariate prognostic value for PFS and OS (P 0.0001) in all of the patients. Howe